An open-label, single dose study to investigate the safety, tolerability and pharmacokinetics of 90mg of GW274150 in adult and elderly RA [rheumatoid arthritis] subjects.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs GW 274150 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 13 Jan 2012 Actual end date (Sep 2005) added as reported by ClinicalTrials.gov.
- 12 Oct 2008 Trial phase changed from I to II as reported by ClinicalTrials.gov
- 15 Oct 2006 New trial record.